CEBPA and acute myeloid leukemia: Since mp30 could sensitize HL‐60 and U937 to Ara‐C treatment, we therefore exposed AML cells to Ara‐C combined with Bay 11‐7082 to assess whether combined utilization could similarly sensitize AML cells without C/EBPα mutation.